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Background: Among people living in detention, substance use is highly prevalent,
including opioid dependence. Opioid agonist treatment (OAT) has been established as
an evidence-based, first-line treatment for opioid dependence. Despite high prevalence of
opioid dependence, conclusive data regarding its prevalence and the OAT practice in
German prisons is scarce; rather, the existing data widely diverges concerning the rates of
people in detention receiving OAT.
Materials andMethods:We conducted a cross-sectional survey of all detention facilities
in Berlin. On the date of data collection, a full census of the routine records was completed
based on the medical documentation system. For each opioid dependent individual, we
extracted sociodemographic data (i.e., age, sex, and non-/German nationality, whether
people experienced language-related communication barriers), information about OAT,
comorbidities (HIV, hepatitis C, schizophrenia), and the detention center, as well as the
anticipated imprisonment duration and sentence type. The data was first analyzed
descriptively and secondly in an evaluative-analytical manner by analyzing factors that
influence the access to OAT of people living in detention.
Results: Among the 4,038 people in detention in the Berlin custodial setting under
investigation, we identified a 16% prevalence of opioid dependence. Of the opioid-
dependent individuals, 42% received OAT; 31% were treated with methadone, 55% were
treated with levomethadone, and 14% were treated with buprenorphine. Access to OAT
seemed mainly dependent upon initial receipt of OAT at the time of imprisonment,
detention duration, the prisons in which individuals were detained, German nationality,
and sex. The overall prevalence of HIV was 4–8%, hepatitis C was 31–42%, and
schizophrenia was 5%.
Conclusions: The prevalence of opioid dependence and access to OAT remains a major
health issue in the custodial setting. OAT implementation must be especially intensified
among male, non-German, opioid-dependent individuals with a short detention period.g August 2020 | Volume 11 | Article 7941
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Frontiers in Psychiatry | www.frontiersin.orTreatment itself must be diversified regarding the substances used for OAT, and
institutional treatment differences suggest the need for a consistent treatment approach
and the standardized implementation of treatment guidelines within local prison’s
standard operating procedures. Testing for infectious diseases should be intensified
among opioid-dependent people living in detention to address scarcely known infection
statuses and high infection rates.Keywords: opioid dependence, opioid agonist treatment, prison, prison health care, substitution substances,
treatment access, treatment variabilityINTRODUCTION
In 2007, the World Health Organization (WHO) identified
dependence on drugs, alcohol, or tobacco as being among the
most common physical illnesses in the worldwide prison healthcare
practice, alongside infections, dental diseases, and chronic disorders
(1). This condition also applies to the German custodial setting;
according to current estimates, 20–50% of people living in German
prisons are addicted to alcohol, 70–85% are nicotine dependent, and
20% are opioid dependent (2). The WHO recommends and
recognizes opioid agonist treatment (OAT) as a fundamental,
evidence-based method in treating opioid dependence (3). The
German Association for Addiction Medicine suggests agonist
treatment as a first-line treatment for diagnosed opioid
dependence (4) because it reduces mortality (5–7), decreases
heroin use, and increases the number of patients retained in
treatment (8, 9). Furthermore, OAT affects the transmission of
infectious diseases by reducing the prevalence of injection drug use
(IDU) (10–12) as well as the risk of hepatitis C and HIV acquisition
(13–16). Several recent studies point out that these results may also
be transferred to the custodial setting (17–20).
Nevertheless, OAT remains a controversial topic in the prison
healthcare sector. OAT is available in nearly all prisons of
Western European countries, but it is often provided under
more restrictive conditions than those present in the broader
community (21). Even if Germany was one of the first European
countries to implement OAT in the custodial setting, it still had
remarkably low rates of prison population receiving OAT twenty
years later (22), while the prevalence of IDU among people in
detention is estimated higher compared to other European
countries (23). Moreover, as in other European countries, high
variability exists in treatment practice on a national level (21, 24).
OAT practice in German prisons even subject to trial in front of
the European Court of Human Rights in 2016 (25). Subsequently,
the German state was condemned for not fulfilling its obligation to
provide independent medical expertise to determine whether or
not the provision of OAT was necessary (26).
Despite its political impact and high prevalence of opioid
dependence, conclusive data regarding prevalence and the OAT
practice in German prisons is scarce. Thus, the estimated prevalence
of opioid dependence in prisons considerably varies depending on
the source (27–29). The estimates concerning the rates of people in
detention receiving OAT are similarly heterogeneous. In 2017, a
large-scale secondary data analysis of pharmacy sales data estimated
that, on a national level, merely 10% of all opioid-dependent peopleg 2in detention received adequate substitution treatment but also
mentioned the high variability between the various federal states
(24). Meanwhile, the results of the national report concerning
substance-related dependence problems suggest that, in Berlin,
52% of all opioid-dependent people in detention receive
substitution treatment (29).
Even if the variability of OAT implementation is emphasized
vividly by these numbers, only few studies focus on the question
which criteria are used in the prison health care practice to admit
individuals to OAT. Scientific literature emphasizes the role of an
existing OAT at the time of imprisonment; it seems to be a main
criterion for access to treatment during detention (27, 30, 31).
Further, some authors discuss that access to OAT depends on
infection with HIV and hepatitis C (27, 32). This may derive
from the evolution of OAT where the treatment was amongst
others first made available to individuals with infectious diseases
(33). Further, a German-wide study that questioned prison
physicians about prevalence of opioid dependence and
availability of OAT suggested that people living in detention
with diagnosed psychosis were more likely to access OAT,
probably in order to achieve mental and psychiatric stability
(27). Additionally, the detention duration is considered a critical
variable in individuals’ access to OAT but is contradictorily
discussed. Some authors argue that agonist treatment is more
likely to be granted to individuals with short-term imprisonment
(27, 30, 33) while other works argue that individuals with a
sentence below two years are more likely to be confronted with
an abstinence-oriented approach (34). More generally, language
barriers seem to have an impact on individuals’ access to
addiction treatments outside prison (35, 36); a fact that most
probably also applies to the custodial setting.
Aims
Our work aimed primarily to identify the prevalence of opioid
dependence and OAT in the custodial setting in Berlin and to
assess the actual OAT practice regarding substances used for
OAT. Further, we aimed to identify factors that affect individuals’
access to OAT in prison.MATERIALS AND METHODS
Setting
We conducted the survey in the Berlin custodial setting, which
comprises six prisons, the youth custody center, and the prisonAugust 2020 | Volume 11 | Article 794
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were living in detention. Sentence types included penal
incarceration, pre-trial detention, juvenile sentence, and
compensation imprisonment, the last of which is a form of
imprisonment assigned to individuals who are “unwilling or
unable to pay a fine for committing a criminal offence” (37). In
each prison, a physician is responsible for the entrance
examination and primary healthcare services (2). OAT is
executed by either general practitioners with additional
qualifications in addiction medicine or by psychiatrists. All
medical interventions performed during detention are to
be documented in the medical section of the electronic
documentation system called Basis-Web.Design
On March 25, 2019, we conducted a cross-sectional survey and
extracted data from the routine records of the 4,038 people in
detention recorded in the medical documentation system. Prior to
analysis, all cases were assigned pseudonyms so that no connections
could be made between cases and the individuals’ names.
Patient and Treatment Information
We used the documentation system’s integrated, advanced
search mode to extract for each detention facility separately
all files marked with either the terms “BTM” (meaning
Betäubungsmittel; an abbreviation for the German term for
narcotics), substitution, detoxification, addiction disease, long-
term substitution, drug addiction, tapered withdrawal, opioid
dependence (corresponding with F11.2 in the International
Classification of Diseases), or polyvalent substance use disorder
(corresponding with F19.2 in the International Classification of
Diseases) (38). Subsequently, we individually investigated the
identified files for documented opioid dependence, as not every
detention center used the same markers and not every marker
exclusively referred to opioid dependence. Individuals were
defined as opioid dependent if a medicinal prescription for
OAT or withdrawal therapy was documented in their files.
That means we focused on opioid dependence during
imprisonment and not on a lifetime prevalence of opioid
dependence. In our clinical routine, we experience that
individuals directly mention substance use towards medical
staff, which facilitates diagnosing substance dependence.
We therefore relied on the detection of opioid dependent
individuals through the documentation system, even if some
individuals may have passed undiagnosed if they did not
mention opioid dependence during diagnostic interviews.
Duplications due to files marked with more than one term
were eliminated. We included polydrug use in the search
categories, since in the clinical routine, the diagnosis is also
assigned to patients who mainly consume opioids alongside a
varied co-usage of additional substances. We did not include
dependence upon substances mainly used for pain management,
such as fentanyl or tramadol, as this concerns only a minority of
opioid users in Germany (39), probably due to restrictive
prescription politics (40). We thus extracted 652 people living
in detention with documented opioid dependence.Frontiers in Psychiatry | www.frontiersin.org 3We obtained sociodemographic data for each individual with
reported opioid dependence including age, sex, non-/German
nationality. We extracted information about their OAT
including the prescribed substance, if OAT was begun prior to
imprisonment, and if OAT was begun or terminated during
imprisonment. Tapered withdrawal with opioids was not
considered an OAT. For information about the detention
setting, we extracted the prison, the anticipated imprisonment
duration, and the sentence type for each individual. Fifteen
opioid-dependent individuals were in preventive detention or
life imprisonment; in these cases, their estimated duration was
not defined. For statistical reasons, we therefore labeled the
detention length using the reports of the German Institute
of Criminology (41, 42). Furthermore, we recorded each
individual’s infection status for HIV and hepatitis C. “No
infectious disease”/”no HIV/hepatitis C” noted in the entrance
examination or documented negative test results were reported
as no infection. Anamnestic infection or positive test results were
reported as infection. If neither was documented, the status was
reported as unknown. The comorbidity of schizophrenia was
also extracted. We analyzed the schizophrenia diagnosis rather
than psychosis because the latter was not documented
consistently. Even if by this manner we could not verify the
influence of psychosis on the access to OAT as assumed by
Schulte et al. (27), we nevertheless included schizophrenia in the
model as we assumed from our experience that schizophrenic
individuals may experience barriers to access treatment due to
their diagnosis. Finally, language-related communication
barriers were analyzed. If the anamnesis contained the term
“yes”, “good”, or “sufficient”, or if no annotation was made about
an individual’s language skills, we recorded “no communication
barriers”, which also signified that the physician and patient may
have had another common language apart from German.
Documentation of the term “no”, “some”, “language barrier”,
“little”, or “broken” in reference to language skills was reported
as a communication barrier.
Approval for the research was obtained from both the
Criminological Service of the Law Enforcement Agency of
Berlin (KrimD 45/3/009/19) and the local ethics committee at
Charité-Universitätsmedizin (EA1/082/19).
Statistical Analysis
For the 652 diagnosed opioid users, we computed general
descriptive statistics for their sociodemographic data and
prevalence. The continuous parameters of age and estimated
detention length are presented respectively as the arithmetic
mean plus the standard deviation and the median plus the
interquartile range. Categorical parameters are indicated as
absolute frequencies and percentages. We formed sub-groups
and compared central tendencies of the continuous variables
using the Mann-Whitney test for the variable detention length
(no normality assumption) and an independent t-test for
the variable age (normality assumption) (43). Categorical
parameters were compared using Pearson’s Chi-square test.
In order to identify the factors that statistically correlated with
the provision of OAT, we calculated binary logistic regressions.
The factors age, sex, non-/German nationality, language-relatedAugust 2020 | Volume 11 | Article 794
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of OAT prior to imprisonment, detention duration, prison, and
sentence type were included as independent variables to assess
their impact on the receipt of OAT during detention. As the
youth custody center offered no OAT, it was excluded from the
regression models; the women’s prison was additionally excluded
because sex was a variable. Thus, a total of 641 people in
detention were included in the models. The variables of
hepatitis C or HIV infection and estimated detention length
achieved missing values, and therefore we applied multiple
imputation (m = 20 imputations). We included the previously
defined independent and dependent variables as well as the
respective outcomes in the imputation model.
For all analyses, p <.05 was considered significant. We
performed the analyses using IBM SPSS Statistics, version 25
and DB-Browser for SQLite, version 3.11.2.RESULTS
Prevalence of Opioid Dependence
On March 25, 2019, 4,038 people were detained in the Berlin
custodial setting. Of these individuals, 652 were documented as
opioid dependent, thus representing 16% of the prison
population (see Table 1). The prevalence of documented
opioid dependence varied between 3% (n = 18/631) in a day-
release prison and 25% (n = 211/857) in prison A.
Prevalence of OAT and Course Details
Of the 652 opioid-dependent people in detention, 274 received
OAT (42%; n = 274/652). All detention facilities except the youth
custody center provided OAT and the substitution rate varied
between 20% (n = 32/153) in prison B and 84% (n = 43/51) in the
women’s prison (see Table 1).
A total of 202 individuals were already receiving OAT at the
time of their imprisonment; of those treatments, 73% (n = 147/
202) were continued without any interruption until the date of
data collection (see Table 2), while 16% (n = 33/202) were ended
at some point during detention and 11% (n = 22/202) at the
beginning of imprisonment. As no OAT was provided in theFrontiers in Psychiatry | www.frontiersin.org 4youth custody center, one individual who received OAT at the
time of imprisonment stopped receiving treatment. At the
women’s prison, all OATs prior to imprisonment were
continued until the date of data collection.
The people receiving OAT during detention and the
individuals without OAT differed statistically significantly
regarding age, nationality, and estimated detention length (see
Table 3).
Three different substances were prescribed for OAT; 31% of
individuals (n = 85/274) were treated with methadone, 55% (n =
151/274) with levomethadone, and 14% (n = 38/274) withTABLE 1 | People living in detention and opioid dependence in the custodial setting in Berlin (March 2019), data is shown as n (%).
Prison A Prison B Prison C Women’s
prison






People living in detention 857 957 594 233 488 631 278 4,038
Opioid dependent people in detention 211 (25%) 153 (16%) 139 (23%) 51 (22%) 69 (14%) 18 (3%) 11 (11%) 652 (16%)
The following percentages refer to the number of opioid dependent individuals
Individuals receiving OAT 108 (51%) 32 (20%) 55 (40%) 43 (84%) 26 (38%) 10 (56%) 0 274 (42%)
Substances used for
OAT
Methadone (%) 23 (21%) 29 (91%) 11 (20%) 12 (28%) 10 (38%) 0 – 85 (31%)
Levomethadone
(%)
67 (62%) 0 39 (71%) 23 (53%) 15 (58%) 7 (70%) – 151 (55%)
Buprenorphine
(%)
18 (17%) 3 (9%) 5 (9%) 8 (19%) 1 (4%) 3 (30%) – 38 (14%)August 2020 | Volume 11 |TABLE 2 | Baseline characteristics of opioid dependent individuals (N=652) in
the custodial setting in Berlin (March 2019), data is shown as n (%), age as mean
[SD, standard deviation], and length of detention period as median [IQR,
interquartile range].
Sex Male 601 (92%)
Female 51 (8%)
Age [years] 37 [SD = 8]
Nationality German 323 (50%)
Non-German 329 (50%)
Language-related communication barriers No 508 (78%)
Yes 144 (22%)
Estimated detention duration [months] 17 [IQR = 25]




Pretrial detention 99 (15%)
Current OAT Total 274 (42%)
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substances varied widely among the different custodial
facilities, ranging from 0–91% for methadone, 0–71% for
levomethadone, and 4–30% for buprenorphine (see Figure 1).
Prevalence of HIV, and Hepatitis C and
Schizophrenia
The hepatitis C status was unknown for 27% (n = 176/652) and
the HIV status for 43% (n = 280/652) of the opioid dependentFrontiers in Psychiatry | www.frontiersin.org 5people in detention. The infection status of both HIV and hepatitis
C was known for 56% (n = 364/652) of the opioid-dependent
individuals, while in 26% (n = 168/652) of the records, no
information was entered for either. The documented infection
status differed significantly between the subgroups (see Table 4).
We therefore calculated the prevalence of HIV and hepatitis C
twice: once related to the overall number of opioid-dependent
people in detention and once related to the number of people in
detention for which the respective infection status was known.
Thus, the overall HIV prevalence was 4% (n = 28/652) and 8% (n =
28/372; see Table 4), respectively, while the overall prevalence of
hepatitis C was 31% (n = 199/652) and 42% (n = 199/
476), respectively.
Thirty schizophrenia cases were reported, which amounted to
an overall prevalence of 5% (n = 30/652) among opioid-
dependent people in detention (see Table 4).Impacts on OAT Provision
In the binominal logistic regression model, the most significant
predictors of OAT provision were female sex [adjusted odds
ratio: 28.575, (95%, CI: 9.057–90.156), p <.000], German
nationality [2.170, (1.330–3.539), p = .002], receipt of OAT at
the time of imprisonment [12.071, (7.175–20.308), p <.000],
estimated detention duration [1.012, (1.005–1.018), p = .001],
compensation imprisonment status [3.383, (1.675–6.833), p =
.001], as well as detention in prison A [6.285, (2.728–14.478), p
<.000] and prison C [3.840, (1.611–9.153), p = .002; see Table 5].
Hepatitis C infection had a statistically significant impact in the
model only preceding imputation [1.977, (1.069–.657), p = .030].TABLE 3 | Descriptive data from the group receiving OAT and the group without
treatment at the day of data collection, data is shown as n (%), age as mean [SD]







Sex Male 231 (84%) 370 (98%) <.000
Female 43 (16%) 8 (2%)
Age [years] 39 [SD = 8] 36 [SD = 8] <.000
Nationality German 190 (69%) 133 (35%) <.000





no 249 (91%) 259 (68%) <.000
yes 25 (9%) 119 (32%)







Penal incarceration 204 (74%) 254 (67%) .045
Pretrial detention 51 (17%) 44 (12%) .013
Compensation
imprisonment
19 (7%) 80 (21%) <.000FIGURE 1 | Substances used for OAT in the Berlin custodial setting, data is shown as n.TABLE 4 | Prevalence of HIV, HCV and schizophrenia among opioid dependent individuals in the overall prison population and different subgroups, data is shown as
n (%).
Total (n = 652) Male (n = 601) Female (n = 51) p value OAT (n = 274) no OAT (n = 378) p value
Both HIV and HCV status known 364 (56%) 344 (57%) 20 (39%) .013 182 (66%) 182 (48%) .000
Both HIV and HCV status unknown 168 (26%) 148 (25%) 20 (39%) .022 47 (17%) 121 (32%) .000
HCV infection* 199 (31/42%) 177 (29/40%) 22 (43/70%) .042/.001 100 (36/45%) 99 (26/39%) .005/.207
HIV infection* 28 (4/8%) 23 (4/7%) 5 (10/25%) .043/.002 16 (6/9%) 12 (3/6%) .098/.432
Schizophrenia 30 (5%) 29 (5%) 1 (2%) .349 11 (4%) 19 (5%) .543August 2020 | Volume 11 |*Prevalence is shown once related to the respective group/once related to the number of individuals for which the respective infection status was known.Article 794
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Prevalence of Opioid Dependence and
OAT
With a 16% prevalence of opioid dependence, our results reveal a
lower rate than do previously conducted studies, which estimated the
prevalence of current or former IDU at 21.9–29.7% among people
living in German prisons (27, 28). This discrepancy may have been
influenced by our definition of opioid dependence, which contrasts
with other studies in that it focuses on actual opioid consumption at
the time of imprisonment rather than a lifetime incidence of
substance injection. Further, it could reflect the overall decrease of
IDU observed in European countries (44) as the data from the
previously cited studies is more than ten years old. More generally,
this result fits within the estimated range of prevalence at 2–38% for
IDU in European prisons (21). The relation of non-German to
German opioid-dependent people in detention corresponds with
those in the overall Berlin custodial setting, as about half of the
people living in Berlin prisons are not of German nationality (45). As
a whole, the results again point out that opioid dependence is more
frequent in the custodial setting than in the community, where it is
estimated at around 3.1/1000 in Berlin as well as in Germany (46).
Our observed OAT rate of 42% is significantly higher than the
estimated 10% of dependent individuals in detention receiving OAT
on the national level (47). The OAT rate in the community can be
estimated at 48% in Berlin (46, 48) and in 2012, the European
Monitoring Center for Drugs and Drug Addiction estimated that at
least one in two of the estimated population of problem opioid users
in Europe receive OAT (49). These statistics suggest that an OAT
rate of 42% in the Berlin custodial setting, especially with a variability
between 0–84%, is still rather low compared to the extramural
practice. One may assert that not all people in detention eligible
for OAT are willing to begin an agonist treatment. Even if this were
true, the results of a study conducted in a remand prison inFrontiers in Psychiatry | www.frontiersin.org 6Switzerland suggest that opioid-dependent individuals who are
entering detention are highly willing to begin OAT (50). This
implication suggests that an OAT rate of 42% is not necessarily
due to an individuals’ lack of interest, but rather may reflect the
ineffective implementation of OAT in the custodial setting.
Substances Used During OAT
Contrarily to the extramural setting, only three substances were
administered alongside individuals’ OATs in the Berlin prisons.
Compared to the extramural practice based on the statistics of
the annual German Report on Drugs and Addiction (48), we
observed that methadone and buprenorphine were used less
often and levomethadone more often. Despite being used in the
extramural setting (48), codeine, dihydrocodeine, diamorphine,
and retarded morphine are not offered in Berlin prisons. Though,
different treatment substances create the opportunity to more
efficiently address individual physical or mental adverse effects
and differences in metabolization (51, 52). As Kourounis et al.
have determined, a lack of pluralism in medication options
creates a treatment design barrier that makes it more difficult
for patients receiving OAT to remain in treatment (53). Thus, the
use of only two different substances in some prisons may reflect a
restricted prescription practice in prison that may present a
significant treatment design barrier.
Access to OAT During Detention
The fact that existing OAT at the time of imprisonment had a
major impact on the access to OAT during detention aligns with
findings from the German and European level (27, 30, 31).
However, a study conducted at the German national level
found that 70% of individuals undergoing OAT at the time
of imprisonment were required to end their treatment upon
incarceration (54) while our results show that 73% of treatments
that began in the extramural system were continued until theTABLE 5 | Association between potential factors and receiving OAT from binary logistic regression after imputation.
Coefficient Standard error p value Adjusted odds ratio BCa 95% Confidence Interval
Lower Upper
Age .009 .015 .555 1.009 .980 1.038
Sex (female) 3.353 .586 .000 28.575 9.057 90.156
German nationality .775 .250 .002 2.170 1.330 3.539
No language-related communication barriers .659 .351 .060 1.933 .971 3.847
Schizophrenia .409 .495 .409 1.505 .570 3.971
HCV infection .288 .263 .275 1.333 .795 2.236
HIV infection .029 .461 .950 1.029 .415 2.550
Receipt of OAT at the time of imprisonment 2.491 .265 .000 12.071 7.175 20.308
Estimated detention duration [months] .012 .003 .001 1.012 1.005 1.018
Sentence type Penal incarceration 1 (reference)
Pretrial detention .488 .617 .429 1.629 .486 5.459
Compensation imprisonment 1.219 .359 .001 3.383 1.675 6.833
Prison Prison D 1 (reference)
Prison for day-release .310 .681 .649 1.363 .359 5.182
Prison A 1.838 .426 .000 6.285 2.728 14.478
Prison C 1.345 .443 .002 3.840 1.611 9.153
Prison B .396 .561 .479 1.487 .495 4.461
Constant -4.369 .738 .000 .013 .003 .054August 2020 | VolumeR² = [.485–.490] (Nagelkerke) [.067–.745] (Hosmer & Lemeshow). Model c²(15) = [258.443–262.042], p < .000.11 | Article 794
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differences in the OAT practices at the transition from the
extramural to the intramural sector across various federal
states. For instance, in Saarland, no prisons are supplied with
OAT medicines, and in Lower Saxony, all prisons are supplied
with such substances (24).
Our research demonstrated lower rates of opioid dependence
among women than previous studies, which estimated dependence
on opioids between 27–50% in the women’s custodial setting (55,
56). However, we found similar to higher rates of OAT provision
which varied between 13–84% in other works (2, 55). It is to note
that the rate of opioid dependence in the women’s prison was still
among the highest in our study. Further a study previously
conducted in the custodial setting in Berlin pointed out that
among women with addiction living in prison, 90% had at least
one other mental disorder (55). This shows that opioid dependent
women remain a small, but vulnerable group in the prison setting,
which needs to be addressed by prison health services.
Furthermore, we were surprised by the impact of the German
nationality on treatment access. In the extramural system, access
to OAT is essentially dependent upon individuals’ access to
healthcare, which is closely associated with nationality and
legal residency status. Assuming that German nationality is an
indicator for individuals’ health insurance status, the extramural
health insurance situation still seems to influence their
intramural access to treatment. This is even more striking
considering that healthcare costs during detention are covered
by the federal states (57).
We observed a significantly higher share of people in
detention with language barriers among those without OAT
than among those who received treatment. This finding suggests
that communication abilities still have a practical impact on
individuals’ receipt of OAT.
In contrast with the findings of other studies (27, 32) and our
expectations, we found that HIV and/or hepatitis C infection did
not seem to be a predictor for the provision of OAT during
detention. This result may be explained by the fact that both the
HIV and hepatitis C infection statuses were exclusively known for
56% of people in detention, which thus renders rather unlikely a
systematic decision regarding whether or not individuals should
begin OAT depending on their infection status. Furthermore, the
fact that infection status was documented significantly more often
among individuals who received OAT during detention suggests
that an individual’s receipt of OAT is associated with a higher rate
of proposed testing for HIV and hepatitis C. Meanwhile, among
people in detention worldwide, HIV and hepatitis C prevalence is
estimated at 3.8 and 15.1%, respectively (58). A recent German
study found that 66% of individuals who inject drugs are infected
with hepatitis C and 4.9% with HIV (39). We determined similar
results with an estimated prevalence of 4–8% for HIV and 31–42%
for hepatitis C among the opioid dependent individuals, showing
that both HIV and hepatitis C still present a major health issue in
the custodial setting. Infection status seems to be less often known
among male opioid dependent individuals without OAT and
among women, while in our results these even presented higher
infection rates than men of both HIV and hepatitis C. TheFrontiers in Psychiatry | www.frontiersin.org 7controlled structure of imprisonment should be used to
systematically propose testing, counselling and treatment of
infectious diseases (39). The supply of OAT should be intensified
as a strategy of harm reduction among others, in order to prevent
new infections among people in detention (17, 19, 20, 39).
Contrary to our expectations, diagnosed schizophrenia had
no statistical impact on provision of OAT. However, we
identified a 5% prevalence for schizophrenia among opioid-
dependent people in detention. As such, schizophrenia remains
an important comorbidity, as its prevalence is higher herein than
in the overall population, where it is estimated at 3.1% (59).
The fact that each month of detention increased a person’s
likelihood to receive OAT may reflect the attitudes of physicians
who prefer to administer OAT to individuals with longer
sentences in order to assure the treatment’s stability and
durability. Meanwhile, the WHO recommends to propose OAT
to people in detention who are not yet receiving such treatment
even if the remainder of their sentence is short, as OAT reduces
both the risk of overdose after release and reincarceration rates (3)
and this further could reduce infection rates with hepatitis C (17).
Eventually, we observed that the access to OAT seemed to
depend on the prison in which individuals were detained. It is
noteworthy that prison D unites two different custodial facilities
with two different medical entities, one of which primarily detains
individuals under compensation imprisonment. Thus,
compensation imprisonment represented a predictor for OAT
most likely due to factors related to this sub-prison. Several
authors discuss differences in attitudes held toward liberal and
harm-reduction drug politics—which translate into different
institutional policies and regulations—as a main reason for the
general hesitation to use OAT in prisons and its high
implementation variability between different federal states (24, 30,
34, 60). Yet the variability of implementation seems not only to be
limited to the national level (24), but also to apply to the federal state
level. This variability in treatment implementation at every
institutional level—within countries and federal states—has been
observed in other European countries (33). It suggests that different
prisons have different OAT practices and that indications for
agonist treatment do not follow a common approach. Another
reason for the variability of implementation may be differences in
the respective prison physicians’ qualifications in addiction
medicine. This observation is even more striking considering
that Berlin represents a federal state and a city at the same time.
It could have been assumed that the geographical closeness and
the institutional frame would lead to a consistent treatment
approach. It is important to consider that, even if OAT
implementation in prison presents certain limitations due to
institutional implications, it remains a setting that may
theoretically offer a low-threshold service for drug users
regarding accessibility barriers (53). The German federal state of
North Rhine-Westphalia has recently shown that the amount of
people in detention receiving OAT could significantly be increased
by a clear statement of the Ministry of Justice that OAT has to be
implemented in prisons as well as treatment recommendations
developed by the medical profession defining a standard of care,
medical education of prison doctors and a monitoring system (61).August 2020 | Volume 11 | Article 794
von Bernuth et al. Opioid Agonist Treatment in PrisonSystematically offering OAT through primary healthcare, based on
existing international and national treatment guidelines for opioid
dependence (3, 4), would reduce selective intake criteria and
consequently improve accessibility. Other European countries
have demonstrated that this approach is both possible and
generally well-accepted by people living in detention (50, 62).
Limitations
When interpreting our findings, it must be noted that all results are
as valid as the documentation provided for analysis. While the
people in detention receiving OAT were quite thoroughly
documented, individuals who did not mention opioid dependence
to medical staff during the entrance examination or during
detention did not appear in our analysis. It is likely that we
overestimated the rate of individuals receiving agonist treatment.
Further, it must be considered that the documentation system
used in the Berlin prison setting was not designed for
epidemiological analysis; this fact most importantly relates to
the estimated prevalence of HIV and hepatitis C. As mentioned
above, the infection statuses were not consistently documented
in the electronic system and we had to rely on documented test
results as well as on anamnestic information. Though,
documented positive or negative test results are more useful
than anamnestic information of “no infectious disease”, as this
statement may imply a summary of negative results but could
also be a simple re-statement of unconfirmed medical history.
Such, each calculated prevalence and its impact on individuals’
access to OAT merely present an approximation.
Eventually, we conducted quantitative, cross-sectional research
that cannot explain all of our findings and does not display long-
term outcomes. Individuals’ perspectives of substitution treatment
remain unknown and are necessary to consider if we are accurately
to assess their needs and experienced barriers to accessing OAT in
prison. Similarly, institutional factors of the prison setting that
affect OAT implementation are only marginally represented in our
study. Our results can therefore be considered a first quantifying
step that necessitates further qualitative research.
CONCLUSION
Our results reveal that opioid dependence remains a major
health issue in the custodial setting that must be further
addressed. By comparing prisons in Berlin to the German
extramural setting, OAT seems to be implemented less often in
the former. OAT implementation in prisons must be intensifiedFrontiers in Psychiatry | www.frontiersin.org 8and treatment itself diversified regarding the substances used
during OAT, especially among male, non-German, opioid-
dependent individuals with a short detention period. The
prison in which individuals are detained has a major impact
on OAT implementation, which suggests that institutional
changes are needed in order to implement a consistent
treatment approach on a federal state level—such as treatment
guidelines for opioid dependence- within local prison’s standard
operating procedures. Such an approach is even more severely
needed considering that OAT is a measure facing high infection
rates of HIV and hepatitis C among opioid-dependent people
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